Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.

Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.

Abstract: The present disclosure provides, in some embodiments, methods for culturing and expanding hematopoietic stem cells (HSPCs) comprising a genomic modification associated with clonal hematopoiesis (CH). These cultured and expanded HSPCs are used, in some embodiments, to identify genes that promote CH, to identify inhibitors of CH, and to inhibit CH.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: The presently disclosed subject matter provides cells comprising a Fas ligand (FasL) polypeptide and a cFLIP polypeptide. In certain embodiments, the cells further comprise an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR), or a TCR like fusion molecule). Also provided are uses of the cells for cell lysis of target cells expressing Fas, and for treating diseases or disorders, e.g., tumors.

Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to DLL3 and methods of using such antibodies or antigen-binding fragments thereof same.

Abstract: The presently disclosed subject matter provides antibodies that mimic TCR recognition of HPV-derived epitopes presented by HLA class I molecules, antigen-recognizing receptors that target HPV-derived epitopes presented by HLA class I molecules, and methods of using such antibodies.

Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule), a Fas ligand polypeptide (FasL), and a gene disruption of a Fas locus. The gene disruption of the Fas locus can improve the activity and/or efficiency of the cells. The presently disclosed cells, compositions, and methods can be used in allogeneic settings.

Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

Abstract: The present disclosure provides organoid co-cultures and methods of using such co-cultures. In particular, the present disclosure provides organoid-immune cell and organoid-bacterial cell co-cultures. The present disclosure further provides methods for testing therapeutic agents using the disclosed organoid co-cultures.

Abstract: The present disclosure provides methods for treating cancer in a subject (by inhibiting e.g., APOBEC3A, APOBEC3B, or REV1), and methods of diagnosing cancer in a subject. Methods of tracking mutagenesis induced by a gene of interest (e.g., APOBEC3A, APOBEC3B, or REV1) and methods of screening for inhibitors and synthetic lethalities are also described herein. Further provided by the present disclosure are cell lines and antibodies for use in the methods described herein.

Abstract: The present disclosure relates to compositions and methods for predicting cancer survival or toxicity in a subject receiving a chimeric antigen receptor (CAR) T cell therapy. The present disclosure further discloses compositions, e.g., pharmaceutical compositions, and methods for treating said subject.

Abstract: The presently disclosed subject matter provides novel T cell receptors (TCRs) that target a mutated RAS protooncogene. The presently disclosed subject matter further provides cells comprising such TCRs. and methods of using such cells for treating cancers associated with RAS.

Abstract: The present disclosure relates to methods for generating sacral neural crest lineage cells and enteric neurons. Also provided are sacral neural crest lineage cells and enteric neurons generated by the presently disclosed methods and compositions comprising such cells. The present disclosure further provides uses of the sacral neural crest lineage cells and enteric neurons for preventing, modeling, and/or treating of enteric nervous system disorders.

Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD33 and methods of using such antibodies or antigen-binding fragments thereof same.

Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.

Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.

Abstract: The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.

Abstract: Aspects of the disclosure provide methods for inhibiting cell proliferation and protein synthesis utilizing an antagonist of nicotinamide adenine dinucleotide kinase 2 (NADK2). In some aspects, these methods are used to treat a disease such as cancer or a disorder such as a fibrotic disorder. Further provided herein are compositions comprising a nutrient-deficient cell culture medium and an antagonist of NADK2.